MedTrace Logo

Entacapone Combination With Imatinib for Treatment of GIST

NCT04006769 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2023-10-18

No results posted yet for this study

Summary

This study evaluates the combination of entacapone and imatinib in the treatment of gastrointestinal stromal Tumors who have progressed on the setting of at least Imatinib and Sunitinib. 5 participants will be included in this open-label observatory study.

Conditions

  • Gastrointestinal Stromal Tumor, Malignant

Interventions

DRUG

Entacapone

Entacapone tablet

DRUG

Imatinib Mesylate

Imatinib Mesylate tablet

Sponsors & Collaborators

  • Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Bin Li, MD · Xiangya Hospital, Central South University, Changsha, Hunan,China,410008

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2022-08-31
Completion
2022-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04006769 on ClinicalTrials.gov